CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-28 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale | −91 | $240.32 | $22K | 13,674 |
| 2025-02-28 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale | −149 | $241.51 | $36K | 13,525 |
| 2025-02-28 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale | −352 | $242.44 | $85K | 13,173 |
| 2025-02-28 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale | −142 | $243.23 | $35K | 13,031 |
| 2025-02-28 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale | −69 | $244.11 | $17K | 12,962 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −27 | $236.51 | $6K | 12,854 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −21 | $238.33 | $5K | 12,833 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −22 | $239.18 | $5K | 12,811 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −48 | $240.32 | $12K | 12,763 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −79 | $241.51 | $19K | 12,684 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −187 | $242.44 | $45K | 12,497 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −75 | $243.23 | $18K | 12,422 |
| 2025-02-28 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −37 | $244.11 | $9K | 12,385 |
| 2025-02-27 | Greenstreet Yvonne Chief Executive Officer | Option exercise | +5,921 | 87,447 | ||
| 2025-02-27 | Greenstreet Yvonne Chief Executive Officer | Option exercise · Restricted Stock Units | −5,921 | 5,921 | ||
| 2025-02-27 | Poulton Jeffrey V. EVP, Chief Financial Officer | Option exercise | +1,908 | 34,694 | ||
| 2025-02-27 | Poulton Jeffrey V. EVP, Chief Financial Officer | Option exercise · Restricted Stock Units | −1,908 | 1,908 | ||
| 2025-02-27 | Tanguler Tolga EVP, Chief Commercial Officer | Option exercise | +1,667 | 14,858 | ||
| 2025-02-27 | Tanguler Tolga EVP, Chief Commercial Officer | Option exercise · Restricted Stock Units | −1,667 | 1,666 | ||
| 2025-02-27 | Garg Pushkal CMO & EVP Dev & Med Affairs | Option exercise | +1,908 | 13,897 |
Page 35 of 41 · 816 trades